Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.33 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.33 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30078498 | 1.00 | NNMT (0.40) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL3736737 | 1.00 | NNMT (0.40) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| SCHEMBL29424844 | 0.98 | NNMT (0.41) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| SCHEMBL126903 | 0.98 | NNMT (0.41) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| SCHEMBL13657692 | 0.83 | NNMT (0.40) | NNMTSIRT2SIRT1 | |
| Hydrochloric Acid SCHEMBL930533 | 0.80 | POLB (0.48) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL30294545 | 0.80 | NNMT (0.52) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 | |
| SCHEMBL6027123 | 0.79 | TXNRD1 (0.51) | RAB9AMAPT | |
| SCHEMBL27235504 | 0.79 | NNMT (0.46) | NNMTSIRT2SIRT1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL30294787 | 0.78 | NNMT (0.38) | NNMTSIRT2SIRT1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955112-A | Two-component system for artificial hair coloring | 汉高股份有限及两合公司 | 2021-06-11 | — | — | CN | claimed |
| US-12583876-B2 | Branched organosilicon compound, method of preparing same, and related compositions | DOW SILICONES CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3493878-B1 | COSMETIC COMPOSITION COMPRISING CURED SILICONE MATERIALS | DOW SILICONES CORP (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12398270-B2 | Acrylate-functional branched organosilicon compound, method of preparing same, and copolymer formed therewith | DOW SILICONES CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| US-12371535-B2 | Branched organosilicon compound, method of preparing same, and copolymer formed therewith | DOW SILICONES CORPORATION (US) | 2025-07-29 | — | — | US | disclosed |
| US-12338259-B2 | Branched organosilicon compound, method of preparing same, and copolymer formed therewith | DOW SILICONES CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-12269833-B2 | Branched organosilicon compound, method of preparing same, and compositions comprising same | DOW SILICONES CORPORATION (US) | 2025-04-08 | — | — | US | disclosed |
| US-12215198-B2 | Branched organosilicon compound, method of preparing same, and compositions comprising same | DOW SILICONES CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240245600-A1 | ORRIS ROOT EXTRACTS, COMPOSITIONS, AND METHODS FOR SKIN APPLICATIONS | ACCESS BUSINESS GROUP INT LLC (US) | 2024-07-25 | — | — | US | disclosed |
| US-11986547-B2 | Cosmetic composition comprising silicone materials | DOW SILICONES CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| EP-2120846-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008107347-A2 | USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS | BASF SE (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20060110379-A1 | Linkage of agents using microparticles | PERICOR SCIENCE, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060104966-A1 | Transglutaminase linkage of agents to tissue | PERICOR SCIENCE, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-6958148-B1 | Linkage of agents to body tissue using microparticles and transglutaminase | PERICOR SCIENCE, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6919076-B1 | Conjugates of agents and transglutaminase substrate linking molecules | PERICOR SCIENCE, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202706-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12215198-B2 | Branched organosilicon compound, method of preparing same, and compositions comprising same | ORC3, OXSR1, OR10J3 | ADRA2B 1845/4885PTGS1 3599/4885GAA 4594/4885 |
| US-12583876-B2 | Branched organosilicon compound, method of preparing same, and related compositions | OXSR1, BRS3, NPSR1 | ADRA2B 993/4885PTGS1 4383/4885GAA 4501/4885 |
| US-12269833-B2 | Branched organosilicon compound, method of preparing same, and compositions comprising same | NR3C2, NR2E3, OXER1 | ADRA2B 1113/4885PTGS1 3886/4885GAA 4768/4885 |
| US-12338259-B2 | Branched organosilicon compound, method of preparing same, and copolymer formed therewith | OXSR1, BRS3, ORC3 | ADRA2B 2224/4885PTGS1 3307/4885GAA 3655/4885 |
| US-12371535-B2 | Branched organosilicon compound, method of preparing same, and copolymer formed therewith | OXSR1, BRS3, OXER1 | ADRA2B 511/4885PTGS1 3490/4885GAA 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.